pamapimod

10/01/2010 - "It is unlikely that pamapimod will be useful in the treatment of rheumatoid arthritis."
10/01/2010 - "The objective of this review was to evaluate the recent clinical trials of pamapimod in subjects with rheumatoid arthritis. "
10/01/2010 - "Pamapimod is a p38α inhibitor being developed for use in the treatment of rheumatoid arthritis. "
06/20/2022 - "Pamapimod is a selective inhibitor of p38 Mitogen-Activated Protein Kinase alpha (p38 MAPKα) that has been extensively clinically evaluated for the treatment of rheumatoid arthritis. "
10/01/2010 - "There is no clear-cut evidence that pamapimod alone or in the presence of methotrexate is efficacious in subjects with rheumatoid arthritis but it does cause adverse effects. "

12/02/2020 - "In this study, we focused on a p38 inhibitor named Pamapimod (PAM) in the effect of CH hypertrophy degeneration. "
12/02/2020 - "Inhibition against p38/MEF2C pathway by Pamapimod protects osteoarthritis chondrocytes hypertrophy."

12/01/2008 - "Our study demonstrates that pamapimod is a potent, selective inhibitor of p38alpha with the ability to inhibit the signs and symptoms of RA and other autoimmune diseases."

06/20/2022 - "These data support the combination of pamapimod and pioglitazone as a potential therapy to reduce duration and severity of disease in COVID-19 patients, an assumption currently evaluated in an ongoing phase II clinical study."
10/20/2023 - "The KINETIC phase 2 randomized controlled trial of oral pamapimod-pioglitazone in non-critically ill COVID-19 inpatients."

10/20/2023 - "The KINETIC phase 2 randomized controlled trial of oral pamapimod-pioglitazone in non-critically ill COVID-19 inpatients."